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Background
Efficacy of standardized short ragweed sublingual immu-
notherapy tablet (SLIT-T), MK-3641 (Merck/ALK; 12
Amb a 1-U of Ambrosia artemisiifolia) treatment on
Canadian ragweed-allergic subjects was assessed using
subgroup analysis of data from 2 multinational, rando-
mized, double-blind, placebo-controlled clinical trials
designed to evaluate ragweed SLIT-T efficacy and safety in
adults with ragweed pollen-induced allergic rhinitis with
or without conjunctivitis (AR/C), with or without asthma.
Methods
We conducted pooled subgroup analysis of data from
2 studies (P05234, n=784; P05233, n=565) investigating
efficacy and safety of once-daily ragweed SLIT-T [1,2]. In
both trials, subjects were randomized to receive ragweed
SLIT-T (of multiple doses tested, 12 Amb a 1-U was
found most effective and is included here) or placebo.
Treatment was started approximately 16 weeks before rag-
weed pollen season (RS) and continued during and after
RS (total, approximately 52 weeks). Subjects recorded
AR/C symptoms in daily e-diaries from randomization to
end of RS. During RS, subjects also recorded AR/C rescue
medication use. The primary efficacy endpoint was the
average total combined score (TCS), the sum of the daily
symptom score (DSS) and daily medication score (DMS)
during peak RS (the 15 consecutive days within RS with
the highest 15-day moving average pollen count).
Results
In the pooled study population of the 2 trials, approxi-
mately 80% of subjects were polysensitized and approxi-
mately 20% had asthma; mean age was approximately 36
years. The pooled Canadian subpopulation included 104
and 94 subjects receiving placebo and 12 Amb a 1-U
SLIT-T respectively. Average pollen count for Canadian
sites was approximately 100 grains/m3 during peak RS.
Canadian subjects receiving 12 Amb a 1-U SLIT-T had a
mean TCS of 5.13 over peak RS, representing a 42%
reduction vs 8.90 for placebo (–3.77; 95% CI, –5.16 to –
2.39). Reductions in the primary endpoint with 12 Amb a
1-U SLIT-T were supported by reductions in components
DSS and DMS in the pooled population. Treatment-emer-
gent adverse events (AEs) were reported for 80.9% and
94.5% of Canadian subjects in placebo and 12 Amb a 1-U
SLIT-T groups respectively; treatment-related AEs were
reported for 33.9% and 80.9% respectively. The majority of
treatment-related AEs were mild, local, application-site
reactions with no reports of serious treatment-related AEs
or systemic allergic reactions.
Conclusions
In pooled subgroup analysis from 2 trials, ragweed SLIT-
T therapy reduced symptom and medication scores in
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Canadian subjects with ragweed pollen-induced AR/C
with or without asthma.
Trial registration
ClinicalTrials.gov Identifiers NCT00783198, NCT00770315.
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